SG10201913160QA - Adam6 mice - Google Patents

Adam6 mice

Info

Publication number
SG10201913160QA
SG10201913160QA SG10201913160QA SG10201913160QA SG10201913160QA SG 10201913160Q A SG10201913160Q A SG 10201913160QA SG 10201913160Q A SG10201913160Q A SG 10201913160QA SG 10201913160Q A SG10201913160Q A SG 10201913160QA SG 10201913160Q A SG10201913160Q A SG 10201913160QA
Authority
SG
Singapore
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
SG10201913160QA
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913160Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201913160QA publication Critical patent/SG10201913160QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SG10201913160QA 2011-02-25 2012-02-24 Adam6 mice SG10201913160QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06

Publications (1)

Publication Number Publication Date
SG10201913160QA true SG10201913160QA (en) 2020-03-30

Family

ID=45998616

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201913160QA SG10201913160QA (en) 2011-02-25 2012-02-24 Adam6 mice
SG2013064159A SG192933A1 (en) 2011-02-25 2012-02-24 Adam6 mice
SG10201913155QA SG10201913155QA (en) 2011-02-25 2012-02-24 Adam6 mice
SG10201405135RA SG10201405135RA (en) 2011-02-25 2012-02-24 Adam6 mice

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG2013064159A SG192933A1 (en) 2011-02-25 2012-02-24 Adam6 mice
SG10201913155QA SG10201913155QA (en) 2011-02-25 2012-02-24 Adam6 mice
SG10201405135RA SG10201405135RA (en) 2011-02-25 2012-02-24 Adam6 mice

Country Status (31)

Country Link
US (12) US8642835B2 (enrdf_load_stackoverflow)
EP (7) EP3744850A1 (enrdf_load_stackoverflow)
JP (8) JP2014507137A (enrdf_load_stackoverflow)
KR (1) KR101387377B1 (enrdf_load_stackoverflow)
CN (2) CN105861548B (enrdf_load_stackoverflow)
AU (5) AU2012243291B2 (enrdf_load_stackoverflow)
BR (1) BR112013021771B1 (enrdf_load_stackoverflow)
CA (1) CA2820824A1 (enrdf_load_stackoverflow)
CY (5) CY1116301T1 (enrdf_load_stackoverflow)
DE (5) DE14154967T1 (enrdf_load_stackoverflow)
DK (6) DK2738258T4 (enrdf_load_stackoverflow)
ES (6) ES2748832T5 (enrdf_load_stackoverflow)
FI (3) FI2578688T4 (enrdf_load_stackoverflow)
HR (5) HRP20191895T4 (enrdf_load_stackoverflow)
HU (5) HUE062552T2 (enrdf_load_stackoverflow)
IL (4) IL226727A (enrdf_load_stackoverflow)
IN (1) IN2013CN07629A (enrdf_load_stackoverflow)
LT (4) LT2738258T (enrdf_load_stackoverflow)
ME (3) ME03732B (enrdf_load_stackoverflow)
MX (3) MX343009B (enrdf_load_stackoverflow)
MY (1) MY172713A (enrdf_load_stackoverflow)
NZ (2) NZ731926A (enrdf_load_stackoverflow)
PL (5) PL2550363T3 (enrdf_load_stackoverflow)
PT (5) PT4067496T (enrdf_load_stackoverflow)
RS (5) RS59929B1 (enrdf_load_stackoverflow)
RU (2) RU2582261C2 (enrdf_load_stackoverflow)
SG (4) SG10201913160QA (enrdf_load_stackoverflow)
SI (5) SI2550363T1 (enrdf_load_stackoverflow)
SM (5) SMT201900744T1 (enrdf_load_stackoverflow)
WO (1) WO2012141798A1 (enrdf_load_stackoverflow)
ZA (1) ZA201305998B (enrdf_load_stackoverflow)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
PL1776383T3 (pl) 2004-07-22 2015-02-27 Univ Erasmus Med Ct Rotterdam Cząsteczki wiążące
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK2792236T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
LT2601298T (lt) 2010-08-02 2017-03-10 Regeneron Pharmaceuticals, Inc. Pelė, kuri gamina rišančius baltymus, apimančius vl domenus
HUE062552T2 (hu) 2011-02-25 2023-11-28 Regeneron Pharma ADAM6 egerek
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
SI3865581T1 (sl) * 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
CA2846319A1 (en) * 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
RU2743589C2 (ru) 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
TR201903439T4 (tr) 2011-12-20 2019-04-22 Regeneron Pharma İnsanlaştırılmış hafif zincirli fareler.
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
MX381210B (es) 2012-03-16 2025-03-12 Regeneron Pharma Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos.
CN104302171B (zh) 2012-03-16 2017-05-03 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
PL2858487T3 (pl) * 2012-06-12 2020-06-01 Regeneron Pharmaceuticals, Inc. Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny
CA2899740A1 (en) 2013-02-06 2014-08-14 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
EP3841876A1 (en) * 2013-03-14 2021-06-30 Erasmus University Medical Center Rotterdam Transgenic mouse for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
MX2018008701A (es) 2016-01-13 2019-06-06 Regeneron Pharma Roedores que tienen una region de diversidad de cadena pesada modificada geneticamente.
EP3416479A1 (en) 2016-02-16 2018-12-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
SG11201809552SA (en) * 2016-05-20 2018-11-29 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
PT4218408T (pt) 2016-06-03 2025-03-26 Regeneron Pharma Roedores que expressam desoxinucleotidil-transferase terminal exógena
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
CN114369157A (zh) 2016-11-04 2022-04-19 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
CA3066569A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
TWI827567B (zh) 2017-12-05 2024-01-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
CA3093060A1 (en) 2018-03-21 2019-09-26 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
IL277353B2 (en) 2018-03-24 2025-05-01 Regeneron Pharma Non-human animals genetically modified to produce therapeutic antibodies against peptide-MHC complexes, methods for their preparation and uses thereof
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
AU2019249273A1 (en) 2018-04-06 2020-10-15 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
CN112135624B (zh) 2018-05-17 2024-07-19 瑞泽恩制药公司 抗cd63抗体、缀合物和其用途
US12102070B2 (en) 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
MX2021009855A (es) 2019-02-22 2021-09-10 Regeneron Pharma Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
JP2022535418A (ja) 2019-06-05 2022-08-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド カッパ遺伝子座から発現される限られたラムダ軽鎖レパートリーを有する非ヒト動物及びその使用
DK3785536T3 (da) * 2019-08-28 2022-03-28 Trianni Inc Adam6-knockin-mus
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
EP4326765A1 (en) 2021-04-20 2024-02-28 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025055311A1 (zh) 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
AU2024329875A1 (en) * 2024-01-02 2025-07-17 Gempharmatech Co., Ltd Animal model generating humanized antibody and construction method thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
PT942968E (pt) 1996-12-03 2008-03-27 Amgen Fremont Inc Anticorpos totalmente humanos que se ligam ao egfr
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
WO2000073323A2 (en) * 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
AU2002309063B8 (en) 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP5252922B2 (ja) 2004-10-19 2013-07-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝的改変についてホモ接合性の動物を生み出すための方法
DE602005011421D1 (de) 2005-06-30 2009-01-15 Borealis Tech Oy Überzug-Schicht für Energie- oder Kommunikationskabel
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
WO2007143168A2 (en) 2006-06-02 2007-12-13 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
CA3038954A1 (en) 2008-09-30 2010-04-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
DK2792236T4 (da) * 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN102711449B (zh) * 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
HUE062552T2 (hu) 2011-02-25 2023-11-28 Regeneron Pharma ADAM6 egerek
SI3865581T1 (sl) 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
RU2743589C2 (ru) 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
TR201903439T4 (tr) 2011-12-20 2019-04-22 Regeneron Pharma İnsanlaştırılmış hafif zincirli fareler.
PL2858487T3 (pl) 2012-06-12 2020-06-01 Regeneron Pharmaceuticals, Inc. Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny

Also Published As

Publication number Publication date
CY1126091T1 (el) 2023-11-15
HRP20230526T1 (hr) 2023-09-01
HRP20192311T4 (hr) 2023-05-12
LT2738258T (lt) 2020-01-10
PT4067496T (pt) 2023-06-07
US9932408B2 (en) 2018-04-03
RU2582261C2 (ru) 2016-04-20
PL2578688T3 (pl) 2020-05-18
HUE046746T2 (hu) 2020-03-30
CN105861548A (zh) 2016-08-17
EP4067496B1 (en) 2023-03-29
NZ776770A (en) 2023-03-31
RU2016109443A (ru) 2018-11-26
RS59661B1 (sr) 2020-01-31
IL268671B (en) 2020-05-31
HRP20200294T1 (hr) 2020-05-29
MX2020009714A (es) 2020-10-07
DE14154918T1 (de) 2014-08-21
EP2578688B1 (en) 2019-07-24
SMT201900744T1 (it) 2020-01-14
MY172713A (en) 2019-12-11
CN103429746A (zh) 2013-12-04
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
US20210105985A1 (en) 2021-04-15
AU2015238806A1 (en) 2015-10-29
SI4067496T1 (sl) 2023-07-31
US20120322108A1 (en) 2012-12-20
EP2578688B2 (en) 2023-02-08
PL4067496T3 (pl) 2023-07-31
ME03537B (enrdf_load_stackoverflow) 2020-04-20
EP3744850A1 (en) 2020-12-02
NZ731926A (en) 2021-07-30
EP2550363B1 (en) 2014-12-10
JP2014110814A (ja) 2014-06-19
JP2022071051A (ja) 2022-05-13
EP2550363A1 (en) 2013-01-30
NZ703609A (en) 2016-04-29
MX343009B (es) 2016-10-21
PL2550363T3 (pl) 2015-05-29
AU2017251802A1 (en) 2017-11-16
FI2738258T4 (fi) 2023-05-05
DK2578688T4 (da) 2023-05-08
DE12192727T1 (de) 2013-07-11
DK2813573T1 (da) 2015-01-12
RU2016109443A3 (enrdf_load_stackoverflow) 2019-07-24
DK4067496T3 (da) 2023-06-26
SMT201900581T1 (it) 2019-11-13
JP2016135143A (ja) 2016-07-28
JP2018143250A (ja) 2018-09-20
US20210105984A1 (en) 2021-04-15
JP2014507137A (ja) 2014-03-27
EP4067496A1 (en) 2022-10-05
PT2738258T (pt) 2019-12-10
CY1122459T1 (el) 2021-01-27
PL2578688T5 (pl) 2023-05-29
SI2738259T1 (sl) 2020-06-30
NZ718688A (en) 2017-07-28
US10072095B2 (en) 2018-09-11
ES2748832T5 (es) 2023-06-08
US20240306617A1 (en) 2024-09-19
EP2578688A1 (en) 2013-04-10
EP2738258A2 (en) 2014-06-04
DK2738259T3 (da) 2020-02-17
JP2015107131A (ja) 2015-06-11
RU2013125717A (ru) 2014-12-10
DK2738259T1 (da) 2014-11-24
DE14154967T1 (de) 2014-08-28
RS59413B2 (sr) 2023-06-30
SG10201405135RA (en) 2014-10-30
IN2013CN07629A (enrdf_load_stackoverflow) 2015-08-07
EP2738259B1 (en) 2019-11-27
CY1122820T1 (el) 2021-05-05
DE14176593T1 (de) 2015-03-05
ES2805364T3 (es) 2021-02-11
DK2550363T3 (en) 2015-03-23
EP2738259A3 (en) 2014-07-30
ZA201305998B (en) 2016-07-27
FI4067496T3 (fi) 2023-05-24
SMT202300173T1 (it) 2023-07-20
SMT202000112T1 (it) 2020-05-08
EP2738259A2 (en) 2014-06-04
CN103429746B (zh) 2016-05-11
US20150210776A1 (en) 2015-07-30
KR101387377B1 (ko) 2014-04-21
CY1122205T1 (el) 2020-11-25
WO2012141798A1 (en) 2012-10-18
SG10201913155QA (en) 2020-02-27
RS53880B1 (en) 2015-08-31
MX2013009649A (es) 2013-09-26
LT2578688T (lt) 2019-11-11
JP2025032218A (ja) 2025-03-11
IL273986A (en) 2020-05-31
ES2748832T3 (es) 2020-03-18
RS59413B1 (sr) 2019-11-29
ES2758974T3 (es) 2020-05-07
IL261243A (en) 2018-10-31
LT4067496T (lt) 2023-06-12
US20180346599A1 (en) 2018-12-06
US9944716B2 (en) 2018-04-17
US20180346598A1 (en) 2018-12-06
RS59929B1 (sr) 2020-03-31
EP2738258B1 (en) 2019-09-25
PL2738258T3 (pl) 2020-08-24
US20140213773A1 (en) 2014-07-31
BR112013021771B1 (pt) 2022-11-16
RU2722373C2 (ru) 2020-05-29
AU2012243291B2 (en) 2015-07-09
BR112013021771A2 (pt) 2017-07-04
CA2820824A1 (en) 2012-10-18
DK2738258T1 (da) 2014-11-24
SMT201500061B (it) 2015-05-05
US20180345760A1 (en) 2018-12-06
SI2738258T2 (sl) 2023-05-31
NZ797720A (en) 2024-09-27
MX375115B (es) 2025-03-06
KR20130116375A (ko) 2013-10-23
DK2738258T4 (da) 2023-05-08
HRP20191895T1 (hr) 2020-01-10
IL226727A (en) 2016-08-31
US20130254911A1 (en) 2013-09-26
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
IL261243B (en) 2019-08-29
US20180362663A1 (en) 2018-12-20
EP2813573A1 (en) 2014-12-17
JP5866127B2 (ja) 2016-02-17
PT2738259T (pt) 2020-02-18
CN105861548B (zh) 2020-01-10
US10694725B2 (en) 2020-06-30
LT2738259T (lt) 2020-03-10
US10905108B2 (en) 2021-02-02
NZ612643A (en) 2015-06-26
RS59661B2 (sr) 2023-06-30
AU2012243291A1 (en) 2013-05-09
IL273986B (en) 2021-04-29
IL268671A (en) 2019-10-31
SI2578688T1 (sl) 2019-11-29
DK2578688T3 (da) 2019-10-28
DK2738258T3 (da) 2019-12-16
CY1116301T1 (el) 2017-02-08
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
ES2770424T3 (es) 2020-07-01
US20150201589A1 (en) 2015-07-23
ME02106B (me) 2015-10-20
ME03732B (me) 2021-01-20
US12207628B2 (en) 2025-01-28
HUE062552T2 (hu) 2023-11-28
EP2738258B2 (en) 2023-02-01
SI2578688T2 (sl) 2023-05-31
RS64280B1 (sr) 2023-07-31
PL2738259T3 (pl) 2020-08-24
PT2550363E (pt) 2015-03-16
AU2022206806A1 (en) 2022-08-18
DE12716101T1 (de) 2013-05-08
HUE046081T2 (hu) 2020-01-28
SI2738258T1 (sl) 2020-01-31
US10577430B2 (en) 2020-03-03
JP2019187446A (ja) 2019-10-31
ES2758974T5 (es) 2023-06-08
DK2578688T1 (da) 2014-11-24
ES2946169T3 (es) 2023-07-13
US10905109B2 (en) 2021-02-02
US8697940B2 (en) 2014-04-15
HRP20191895T4 (hr) 2023-05-12
US8642835B2 (en) 2014-02-04
HK1201292A1 (en) 2015-08-28
AU2020201279A1 (en) 2020-03-12
EP2738258A3 (en) 2014-09-24
HRP20150262T1 (hr) 2015-04-10
DK4067496T5 (da) 2024-07-22
HUE024534T2 (hu) 2016-01-28
ES2532487T3 (es) 2015-03-27
SG192933A1 (en) 2013-09-30
HK1174490A1 (en) 2013-06-14
HRP20192311T1 (hr) 2020-03-20
FI2578688T4 (fi) 2023-05-05

Similar Documents

Publication Publication Date Title
IL273986B (en) adam6 mice
AP2014007621A0 (en) 2-Thiopyrimidinones
AU339404S (en) Pen
GB201109865D0 (en) Touchiness interaction
AP00723S1 (en) Autorickshaw
AU2011303V (en) Silverado Dianella tasmanica
AU339857S (en) Orchidometer
AU338110S (en) Barstool
AU338420S (en) Kettlebell
AP2011000390S (en) Kuppkraft
AU2011035V (en) DBK02 Babingtonia virgata